Donor-Derived Cell-Free DNA for Diagnosing Subclinical Rejection: A Pilot Multicenter Study in Japanese Living-Donor Kidney Transplantation [0.03%]
供者来源的无细胞DNA诊断日本活体供肾移植受者的亚临床排斥反应：一项多中心研究试点研究
Toshihito Hirai,Taro Banno,Kazuya Omoto et al.
Toshihito Hirai et al.
Diagnostic performance of dd-cfDNA for subclinical antibody-mediated rejection (AMR) was evaluated at 1.0% and 0.5% cut-off thresholds. Results: Eight patients (11.0%) were diagnosed with subclinical active AMR.
Multicenter Study
Clinical transplantation. 2025 Jul;39(7):e70221. DOI:10.1111/ctr.70221 2025
The Impact of Non-Donor-Specific HLA Antibodies on Antibody-Mediated Rejection in Pediatric Kidney Transplant Recipients [0.03%]
非供体特异性人类白细胞抗原抗体对儿童肾移植受者的抗体介导的排斥反应的影响
Maria Sangermano,Vittoria Soncin,Maria Auciello et al.
Maria Sangermano et al.
While the pathogenic role of donor-specific anti-HLA antibodies (DSAs) in long-term immune-mediated injury after kidney transplantation is well established, the clinical relevance of non-donor-specific antibodies (nDSAs), also detected in t...
Acute Antibody-Mediated Rejection Associated with Anti-MICA Antibodies in Long-Term Kidney Transplant: A Case Study [0.03%]
针对抗MICA抗体的急性抗体介导排斥反应一例长期存活肾移植患者的病例报道
Hiroaki Yonishi,Tomoko Namba-Hamano,Shigeaki Nakazawa et al.
Hiroaki Yonishi et al.
Introduction: Advances in immunosuppressive therapy have improved kidney transplant outcomes; however, antibody-mediated rejection (ABMR) still affects graft survival.
Case Reports
Nephron. 2025 Jun 24:1-12. DOI:10.1159/000546963 2025
Rictor Ameliorates Acute Antibody-Mediated Rejection Following Kidney Transplantation by Suppressing Macrophage M1 Polarization Through p65-NLRP3 Axis [0.03%]
赖藤蛋白通过p65-NLRP3轴抑制巨噬细胞M1极化从而改善抗体介导的急性肾移植排斥反应
Bin Ni,Chengcheng Yang,Junqi Zhang et al.
Bin Ni et al.
Antibody-mediated rejection (ABMR) represents the leading cause of kidney allograft failure over a long term after transplantation. Early infiltration of macrophages predicts the adverse outcome of grafts, yet the underlying mechanisms rema...
Donor-specific antibodies against HLA-C, HLA-DP and HLA-DQ and their implications in kidney transplantation [0.03%]
供者特异性抗体针对HLA-C、HLA-DP和HLA-DQ及其对肾脏移植的影响
Muhammad Abdul Mabood Khalil,Nihal Mohammed Sadagah,Ishida Hediki et al.
Muhammad Abdul Mabood Khalil et al.
Interest in these antigens and antibodies grew when cases of acute antibody-mediated rejection (AMR), mixed rejections, chronic AMR, and reduced graft survival were reported with DSAs against these antigens.
Katharina Wirths,Michael Thomas,Georg Dieplinger et al.
Katharina Wirths et al.
Conclusions: The frequent coincidence of transplant arteriopathy and indicators of antibody-mediated rejection suggests that this arterial remodelling could indeed be antibody-mediated rejection chronicity.
Efficacy of waitlist desensitization for lung candidates is limited by antibody rebound [0.03%]
等待名单上的脱敏治疗因抗体反弹而难以用于肺移植候选人
David Pinelli,Jennifer Wright,Amanda Kamar et al.
David Pinelli et al.
HLA antibodies remain a barrier to lung transplantation due to the risk of antibody-mediated rejection (AMR). Desensitization is an option to lower antibody levels and increase access to transplant by reducing risk of AMR.
Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation [0.03%]
国际心肺移植学会关于心脏移植中抗体和抗体介导的排斥反应的新认识共识会议纪要摘要
Jon Kobashigawa,Andreas Zuckermann,Adriana Zeevi et al.
Jon Kobashigawa et al.
The understanding of circulating antibodies and their relationship to antibody-mediated rejection (AMR) has yet to be fully elucidated in heart transplantation. Circulating antibodies are important in both pretransplant and post-transplant.
Expression of Immune-Related Genes and Possible Regulatory Mechanisms in Chronic Antibody-Mediated Rejection after Kidney Transplantation [0.03%]
慢性抗体介导的肾移植排斥反应相关免疫基因表达及可能的调控机制
Chonghao Sun,Haotian Tan,Changyu Ma et al.
Chonghao Sun et al.
However, their expression patterns and potential regulatory pathways in patients with chronic antibody-mediated rejection (cABMR) post-kidney transplantation remain poorly understood.
Daratumumab for Treatment of Acute Antibody-Mediated Rejection in a Pediatric Kidney Transplant Recipient [0.03%]
达雷珠单抗治疗一名儿童肾移植受者的急性抗体介导性排斥反应
Hailey Connolly,Ally Watson,Michael Wynd et al.
Hailey Connolly et al.
Background: Daratumumab, an anti-CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody-mediated rejection (ABMR) following kidney transplantation in adults.
Case Reports
Pediatric transplantation. 2025 Aug;29(5):e70116. DOI:10.1111/petr.70116 2025
耗时 0.13696 秒，为您在
48285708
条记录里面共找到 2966 篇文章 [XML]